Erlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation
Tyrosine kinase inhibitors of the first, second and third generations are the main treatment method for non-small cell lung cancer with EGFR mutation. About 60% of patients progressing on a first-generation or second-generation tyrosine kinase inhibitor acquire T790M mutation. An alternative is firs...
Gardado en:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado: |
Remedium Group LLC
2021-08-01
|
| Series: | Медицинский совет |
| Assuntos: | |
| Acceso en liña: | https://www.med-sovet.pro/jour/article/view/6247 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|